EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma

XueYin Xu, Lian Tang, XiangHua Piao, ShaoQing Zhan, Yong Chen, PanFeng Feng iD

PLOS One · 14.05.2026 · 21 (5) · e0349044

DOI: 10.1371/journal.pone.0349044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 14.05.2026. Verfasst von XueYin Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Nantong First People's Hospital, Southeast University, Nantong, Jiangsu, China. Hauptthemen laut MEDLINE: Bevacizumab, Liver Neoplasms, Carcinoma, Hepatocellular, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To compare the cost-effectiveness of dual-agent group (finotonlimab combined with a bevacizumab biosimilar) (SCT510) versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HCC) from the perspective of the Chinese healthcare system.

Methods

Based on the results of a Phase III clinical trial, a three-state partitioned survival model was constructed. The primary outcomes of the model included total costs, total quality-adjusted life years (QALYs), and the incremental cost-effectiveness ratio (ICER). Cost-effectiveness analysis was employed to evaluate the economic efficiency of the dual-agent group compared to the sorafenib group as first-line treatment for advanced HCC. The model cycle length was set at 3 weeks, with a time horizon of 10 years and a discount rate of 4.5%. The willingness-to-pay (WTP) threshold was set at three times China’s 2025 per capita gross domestic product (GDP) (299,400 CNY). One-way sensitivity analysis and probabilistic sensitivity analysis were conducted to assess the robustness of the results.

Results

The ICER for the dual-agent group compared to the sorafenib group, calculated based on QALYs, was 859,053.76 CNY/QALY, which is higher than the WTP threshold (299,400 CNY). One-way sensitivity analysis indicated that parameters such as utility value in the PD state, utility value in the PFS state, the cost of finotonlimab and bevacizumab biosimilar had a significant impact on the ICER, while other parameters had minimal influence. The base-case analysis results were robust. Probabilistic sensitivity analysis showed that at a WTP threshold of 299,400 CNY, the probability of the dual-agent group being cost-effective was 0%. When the WTP threshold was approximately 842,000 CNY, the two groups had equal probability of being cost-effective. The probabilistic sensitivity analysis results were consistent with the base-case analysis.

Conclusion

From the perspective of the Chinese healthcare system, finotonlimab combined with a bevacizumab biosimilar is not cost-effective as first-line treatment for advanced HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabLiver NeoplasmsCarcinoma, HepatocellularAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, HumanizedHumansCost-Benefit AnalysisCost-Effectiveness AnalysisQuality-Adjusted Life YearsChinaSorafenib

Substanzen

BevacizumabAntibodies, Monoclonal, HumanizedSorafenib

Autor:innen und Institutionen

  • Department of Pharmacy, Nantong First People's Hospital, Southeast University, Nantong, Jiangsu, China.
  • Department of Pharmacy, Jiangwan Hospital of Shanghai Hongkou District, Shanghai, China.
  • Nantong Key Laboratory of Innovative Research on Rheumatology and Immunology‌‌, Nantong, Jiangsu, China.
  • Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu, China.

ORCID-Profile: PanFeng Feng

Zitieren

APA

Xu, X., Tang, L., Piao, X., Zhan, S., Chen, Y., & Feng, P. (2026). Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma. PLOS One, 21(5), e0349044. https://doi.org/10.1371/journal.pone.0349044

Vancouver

Xu X, Tang L, Piao X, Zhan S, Chen Y, Feng P. Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma. PLOS One. 2026;21(5):e0349044. doi:10.1371/journal.pone.0349044

BibTeX
@article{Xu2026,
  author = {Xu, XueYin and Tang, Lian and Piao, XiangHua and Zhan, ShaoQing and Chen, Yong and Feng, PanFeng},
  title = {Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {5},
  pages = {e0349044},
  doi = {10.1371/journal.pone.0349044}
}
Kostenlos starten →